| Name | Title | Contact Details |
|---|
Kluwer Health International is a Bridgewater, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
NextGate`s mission is to address the fundamental challenge of data management in the healthcare industry: the uncertainties and missed opportunities caused by duplicate and disconnected records in a data population. While implementing interface engine technology for hospitals in the early 1990s, we noticed a troubling trend – as application systems became integrated and exchanged data with each other, problems caused by duplicate and incomplete patient records (previously confined to one system and its MPI) multiplied and contaminated the data quality of other systems. Because this technical issue could impact a patient`s health, we made it our goal to find a solution. The result was MatchMetrix®, a technology platform that invokes probabilistic and other algorithms to identify duplicate and potentially duplicate records within a single data set or across multiple data sets. All records are assigned a unique ID that serves as an enterprise-wide universal key for accurate identification and efficient data exchange. Duplicate records are merged, related records are linked together, and all of them are indexed into a trusted, consistent, and reliable registry accessible to any authorized application or user. We continue to develop solutions that help manage information that facilitates care team collaboration with accuracy and reliability.
Foresee is a Taiwan and US-based biopharmaceutical company listed on the Taipei Exchange (6576.TWO). Foresee`s R&D efforts are focused in two key areas, namely its unique stabilized injectable formulation (SIF) depot delivery technology with derived drug products targeting specialty markets, and secondly its transformative preclinical and clinical first-in-class NCE programs targeting rare and severe disease areas with high unmet needs. Foresee`s product portfolio includes late stage and early stage programs. CAMCEVI® 42 mg is now approved in the U.S. and under regulatory review in the EU. Additionally, U.S. and EU regulatory submissions are in preparation for CAMCEVI® 21 mg. FP-025 – a highly selective oral MMP-12 inhibitor targeting inflammatory and fibrotic diseases, currently in Phase 2/3 studies, including a Phase 2/3 study for COVID-19 virus-induced acute respiratory distress syndrome (ARDS). FP-045 – a highly selective oral small molecule allosteric activator of ALDH2, a mitochondrial enzyme, for which a Phase 1b/2 study is currently planned for Fanconi Anemia.
Rocky Mountain PACE is a healthcare organization that provides coordinated health care services for older adults through the PACE model of care (Program of All-Inclusive Care for the Elderly). Their mission is to improve lives, optimize wellness, and p...
Greer Laboratories Inc. is one of the leading companies in Healthcare, Pharmaceuticals, and Biotech industry. Greer Laboratories Inc. is based in Lenoir, NC. You can find more information on Greer Laboratories Inc. at www.greerlabs.com